3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
142
Myelodysplastic Syndromes
66
Leukemia, Myelomonocytic, Chronic
33
Neoplasms
17
Leukemia
16
Recurrence
14
Hematologic Neoplasms
14
Multiple Myeloma
11
Lymphoma, Non-Hodgkin
9
Lymphoma
7
Carcinoma, Non-Small-Cell Lung
6
Primary Myelofibrosis
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Myeloproliferative Disorders
5
Lymphoma, Large B-Cell, Diffuse
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Neoplasm Metastasis
4
Leukemia, Myeloid
4
Hodgkin Disease
4
Hematologic Diseases
4
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Lung Neoplasms
3
Glioblastoma
3
Breast Neoplasms
3
Anemia, Refractory, with Excess of Blasts
3
Urinary Bladder Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma
2
Renal Insufficiency
2
Interventions
avapritinib
5
midostaurin
2
masitinib
2
ripretinib
1
nilotinib
1
Interviews as Topic
1
Imatinib Mesylate
1
Azacitidine
1
AK002
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Mastocytosis, Systemic
×
Azacitidine
×
Clear all
NCT05609942
2025-04-10
AZURE
Blueprint Medicines Corporation
Phase 1
Terminated
9 enrolled